PROTEOMICS INTERNATIONAL LABORATORIES LTD - Announcements

0.00%

38.0¢

Market Cap $62.19M

Healthcare Biotechnology

Proteomics International Laboratories Ltd is an Australia-based medical technology... Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identified up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

PIQ	Proteomics to showcase PromarkerD at BIO Convention		03/06/19	251.71KB	Share
PIQ	Exercise of Options - Secondary Trading Notice & Appendix 3B		23/05/19	1.5MB	Share
PIQ	Appendix 4C - March 2019 Quarterly Report	PRICE SENSITIVE	24/04/19	422.74KB	Share
PIQ	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	27/02/19	4.31MB	Share
PIQ	US patent for identifying drugs for abnormal kidney function	PRICE SENSITIVE	21/02/19	227.92KB	Share
PIQ	Upcoming release from voluntary escrow		18/02/19	224.84KB	Share
PIQ	Exercise of Options - Secondary Trading Notice & Appendix 3B		04/02/19	427.52KB	Share
PIQ	Appendix 4C - December 2018 Quarterly Report	PRICE SENSITIVE	30/01/19	369.58KB	Share
PIQ	PromarkerD US market update	PRICE SENSITIVE	24/01/19	245.19KB	Share
PIQ	Exercise of Options - Secondary Trading Notice & Appendix 3B		15/01/19	569.06KB	Share
PIQ	Exercise of Options - Secondary Trading Notice & Appendix 3B		03/12/18	609.98KB	Share
PIQ	Proteomics signs PromarkerD agreement with US big pharma	PRICE SENSITIVE	26/11/18	259.78KB	Share
PIQ	Change of directors' interest notices		22/11/18	553.61KB	Share
PIQ	Secondary trading notice		22/11/18	195.81KB	Share
PIQ	Appendix 3B - Issue of Director Options and Shares		22/11/18	175.38KB	Share
PIQ	Final Director's Interest Notice		22/11/18	160.83KB	Share
PIQ	Results of Meeting		22/11/18	489.12KB	Share
PIQ	Proteomics AGM Presentation		22/11/18	1.41MB	Share
PIQ	Adelaide Equity & Scintilla Capital appointed as advisors		14/11/18	219.69KB	Share
PIQ	PromarkerD kit version complete- commercial release imminent	PRICE SENSITIVE	09/11/18	359.96KB	Share
PIQ	Appendix 4C - September 2018 Quarterly Report	PRICE SENSITIVE	30/10/18	363.16KB	Share
PIQ	Diabetic kidney disease test enters Europe & Export Award	PRICE SENSITIVE	24/10/18	232.1KB	Share
PIQ	Proteomics Non-Executive Director Dr Dunlop to retire at AGM		23/10/18	215.68KB	Share
PIQ	Notice of Annual General Meeting/Proxy Form		23/10/18	835.35KB	Share
PIQ	Proteomics receives $834k in R&D Tax Incentive	PRICE SENSITIVE	17/10/18	216.21KB	Share
PIQ	Proteomics receives $928k from sale of shareholding in CPR		05/10/18	214.72KB	Share
PIQ	Proteomics & Atturos partner to target diagnostics in Europe	PRICE SENSITIVE	19/09/18	259.06KB	Share
PIQ	Proteomics to receive $928k from sale of shareholding in CPR	PRICE SENSITIVE	12/09/18	220.39KB	Share
PIQ	Annual Report to shareholders		28/08/18	9.38MB	Share
PIQ	Preliminary Final Report	PRICE SENSITIVE	28/08/18	203.06KB	Share
PIQ	Corporate Governance Statement and Appendix 4G		28/08/18	353.65KB	Share
PIQ	Diagnostics update- Pipeline yields potential new biomarkers	PRICE SENSITIVE	23/08/18	345.27KB	Share
PIQ	Appendix 4C - June 2018 Quarterly Report	PRICE SENSITIVE	30/07/18	877.86KB	Share
PIQ	Proteomics secures major contract - nears cash flow positive	PRICE SENSITIVE	17/07/18	228.26KB	Share
PIQ	Further information on new licence deals in USA and Mexico	PRICE SENSITIVE	21/06/18	221.26KB	Share
PIQ	Proteomics signs deal with Patia for PromarkerD in Mexico	PRICE SENSITIVE	18/06/18	231.51KB	Share
PIQ	Proteomics signs deal to launch PromarkerD test in US market	PRICE SENSITIVE	28/05/18	244.27KB	Share
PIQ	Appendix 3B - Issue of Employee Options		22/05/18	175.83KB	Share
PIQ	Appendix 4C - March 2018 Quarterly Report	PRICE SENSITIVE	26/04/18	809.8KB	Share
PIQ	Change of Directors' Interest Notices		23/04/18	338.45KB	Share
PIQ	Europe PromarkerD patent granted for diabetic kidney disease	PRICE SENSITIVE	19/04/18	216.5KB	Share
PIQ	Underwriters take final $342,000 of Proteomics Options	PRICE SENSITIVE	16/04/18	225.17KB	Share
PIQ	Change in substantial holding		16/04/18	11.29MB	Share
PIQ	Change in substantial holding		16/04/18	1.4MB	Share
PIQ	Change in substantial holding		16/04/18	115.92KB	Share
PIQ	Appendix 3B		16/04/18	375.15KB	Share
PIQ	Secondary trading notice		16/04/18	207.33KB	Share
PIQ	Conversion of 90% of Proteomics Options raises of $3m	PRICE SENSITIVE	06/04/18	225.84KB	Share
PIQ	Change of Director's Interest Notice		06/04/18	234.69KB	Share
PIQ	Appendix 3B - Exercise of options		06/04/18	175.61KB	Share
PIQ	Secondary trading notice		06/04/18	207.23KB	Share
PIQ	Change of Director's Interest Notice		29/03/18	191.24KB	Share
PIQ	Appendix 3B - Exercise of options		29/03/18	374.98KB	Share
PIQ	Secondary Trading Notice		29/03/18	153.96KB	Share
PIQ	Directors Exercise PIQ Options	PRICE SENSITIVE	23/03/18	224.91KB	Share
PIQ	Change of Directors' Interest Notices		23/03/18	860.1KB	Share
PIQ	Appendix 3B - Exercise of options		23/03/18	374.82KB	Share
PIQ	Secondary Trading Notice		23/03/18	166.47KB	Share
PIQ	Appendix 3B - Expiry of Options		15/03/18	491.59KB	Share
PIQ	Proteomics secures underwriting - PIQ Options to raise $3.4m	PRICE SENSITIVE	14/03/18	224.38KB	Share
PIQ	Secondary trading notice		08/03/18	207.24KB	Share
PIQ	Appendix 3B		08/03/18	380.01KB	Share
PIQ	Proteomics launches PromarkerD	PRICE SENSITIVE	07/03/18	230.91KB	Share
PIQ	Proteomics completes investment in CPR Pharma Services		05/03/18	214.91KB	Share
PIQ	Appendix 3B		05/03/18	177.62KB	Share
PIQ	Secondary trading notice		05/03/18	161.47KB	Share
PIQ	Expiry of Options - Letter to Option Holders		19/02/18	1.15MB	Share
PIQ	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	16/02/18	1.22MB	Share
PIQ	Appendix 3B		15/02/18	388.02KB	Share
PIQ	Proteomics International Investor Presentation		07/02/18	3.75MB	Share
PIQ	Proteomics International Investor conference call		06/02/18	205.75KB	Share
PIQ	Proteomics International Options PIQO Exercised		05/02/18	209.46KB	Share
PIQ	Appendix 3B		05/02/18	171.02KB	Share
PIQ	Strategic alliance and investment in CPR Pharma Services	PRICE SENSITIVE	02/02/18	229.41KB	Share
PIQ	PromarkerD diabetic kidney disease patent granted in Japan	PRICE SENSITIVE	29/01/18	239.31KB	Share
PIQ	Appendix 4C - December 2017 Quarterly Report	PRICE SENSITIVE	25/01/18	336.46KB	Share
PIQ	Proteomics partners diagnostic test with Dimerix kidney drug		14/12/17	233.2KB	Share
PIQ	DXB: Proteomics partnership to improve treatment of CKD	PRICE SENSITIVE	14/12/17	134.42KB	Share
PIQ	Proteomics joins major health study to target lung disease	PRICE SENSITIVE	04/12/17	233.22KB	Share
PIQ	Results of Meeting		28/11/17	626.64KB	Share
PIQ	Proteomics AGM Presentation		28/11/17	3.19MB	Share
PIQ	PromarkerD predictive diagnostic test to launch in Q1 2018	PRICE SENSITIVE	27/11/17	263.58KB	Share
PIQ	Initial Director's Interest Notice		23/11/17	316.4KB	Share
PIQ	Proteomics strengthens Board and Business Development team		22/11/17	285.98KB	Share
PIQ	Appendix 3B - Issue of Employee Options		03/11/17	175.37KB	Share
PIQ	Notice of Annual General Meeting/Proxy Form		27/10/17	1.46MB	Share
PIQ	Proteomics partnered consortium to receive $2 million	PRICE SENSITIVE	26/10/17	207.04KB	Share
PIQ	Appendix 4C - September 2017 Quarterly Report	PRICE SENSITIVE	25/10/17	343.23KB	Share
PIQ	Proteomics receives R&D tax incentive	PRICE SENSITIVE	10/10/17	219.89KB	Share
PIQ	Change in substantial holding		18/09/17	7.82MB	Share
PIQ	Change of Director's Interest Notice		13/09/17	124.95KB	Share
PIQ	PromarkerD predictive test results published - Diabetes Care	PRICE SENSITIVE	06/09/17	251.98KB	Share
PIQ	Annual Report to shareholders		31/08/17	10.53MB	Share
PIQ	Corporate Governance Statement and Appendix 4G		31/08/17	349.5KB	Share
PIQ	Preliminary Final Report	PRICE SENSITIVE	31/08/17	693.33KB	Share
PIQ	Appendix 3B		17/08/17	757.5KB	Share
PIQ	Results of Meeting		17/08/17	548.19KB	Share
PIQ	US PromarkerD patent expanded to all kidney disease	PRICE SENSITIVE	16/08/17	230.17KB	Share
PIQ	Appendix 4C - corrected	PRICE SENSITIVE	28/07/17	773.3KB	Share
PIQ	Appendix 4C - June 2017 Quarterly Report	PRICE SENSITIVE	27/07/17	746.98KB	Share

PIQ Proteomics to showcase PromarkerD at BIO Convention
03/06/19		251.71KB	Share
PIQ Exercise of Options - Secondary Trading Notice & Appendix 3B
23/05/19		1.5MB	Share
PIQ Appendix 4C - March 2019 Quarterly Report
24/04/19	PRICE SENSITIVE	422.74KB	Share
PIQ Appendix 4D and Interim Financial Report
27/02/19	PRICE SENSITIVE	4.31MB	Share
PIQ US patent for identifying drugs for abnormal kidney function
21/02/19	PRICE SENSITIVE	227.92KB	Share
PIQ Upcoming release from voluntary escrow
18/02/19		224.84KB	Share
PIQ Exercise of Options - Secondary Trading Notice & Appendix 3B
04/02/19		427.52KB	Share
PIQ Appendix 4C - December 2018 Quarterly Report
30/01/19	PRICE SENSITIVE	369.58KB	Share
PIQ PromarkerD US market update
24/01/19	PRICE SENSITIVE	245.19KB	Share
PIQ Exercise of Options - Secondary Trading Notice & Appendix 3B
15/01/19		569.06KB	Share
PIQ Exercise of Options - Secondary Trading Notice & Appendix 3B
03/12/18		609.98KB	Share
PIQ Proteomics signs PromarkerD agreement with US big pharma
26/11/18	PRICE SENSITIVE	259.78KB	Share
PIQ Change of directors' interest notices
22/11/18		553.61KB	Share
PIQ Secondary trading notice
22/11/18		195.81KB	Share
PIQ Appendix 3B - Issue of Director Options and Shares
22/11/18		175.38KB	Share
PIQ Final Director's Interest Notice
22/11/18		160.83KB	Share
PIQ Results of Meeting
22/11/18		489.12KB	Share
PIQ Proteomics AGM Presentation
22/11/18		1.41MB	Share
PIQ Adelaide Equity & Scintilla Capital appointed as advisors
14/11/18		219.69KB	Share
PIQ PromarkerD kit version complete- commercial release imminent
09/11/18	PRICE SENSITIVE	359.96KB	Share
PIQ Appendix 4C - September 2018 Quarterly Report
30/10/18	PRICE SENSITIVE	363.16KB	Share
PIQ Diabetic kidney disease test enters Europe & Export Award
24/10/18	PRICE SENSITIVE	232.1KB	Share
PIQ Proteomics Non-Executive Director Dr Dunlop to retire at AGM
23/10/18		215.68KB	Share
PIQ Notice of Annual General Meeting/Proxy Form
23/10/18		835.35KB	Share
PIQ Proteomics receives $834k in R&D Tax Incentive
17/10/18	PRICE SENSITIVE	216.21KB	Share
PIQ Proteomics receives $928k from sale of shareholding in CPR
05/10/18		214.72KB	Share
PIQ Proteomics & Atturos partner to target diagnostics in Europe
19/09/18	PRICE SENSITIVE	259.06KB	Share
PIQ Proteomics to receive $928k from sale of shareholding in CPR
12/09/18	PRICE SENSITIVE	220.39KB	Share
PIQ Annual Report to shareholders
28/08/18		9.38MB	Share
PIQ Preliminary Final Report
28/08/18	PRICE SENSITIVE	203.06KB	Share
PIQ Corporate Governance Statement and Appendix 4G
28/08/18		353.65KB	Share
PIQ Diagnostics update- Pipeline yields potential new biomarkers
23/08/18	PRICE SENSITIVE	345.27KB	Share
PIQ Appendix 4C - June 2018 Quarterly Report
30/07/18	PRICE SENSITIVE	877.86KB	Share
PIQ Proteomics secures major contract - nears cash flow positive
17/07/18	PRICE SENSITIVE	228.26KB	Share
PIQ Further information on new licence deals in USA and Mexico
21/06/18	PRICE SENSITIVE	221.26KB	Share
PIQ Proteomics signs deal with Patia for PromarkerD in Mexico
18/06/18	PRICE SENSITIVE	231.51KB	Share
PIQ Proteomics signs deal to launch PromarkerD test in US market
28/05/18	PRICE SENSITIVE	244.27KB	Share
PIQ Appendix 3B - Issue of Employee Options
22/05/18		175.83KB	Share
PIQ Appendix 4C - March 2018 Quarterly Report
26/04/18	PRICE SENSITIVE	809.8KB	Share
PIQ Change of Directors' Interest Notices
23/04/18		338.45KB	Share
PIQ Europe PromarkerD patent granted for diabetic kidney disease
19/04/18	PRICE SENSITIVE	216.5KB	Share
PIQ Underwriters take final $342,000 of Proteomics Options
16/04/18	PRICE SENSITIVE	225.17KB	Share
PIQ Change in substantial holding
16/04/18		11.29MB	Share
PIQ Change in substantial holding
16/04/18		1.4MB	Share
PIQ Change in substantial holding
16/04/18		115.92KB	Share
PIQ Appendix 3B
16/04/18		375.15KB	Share
PIQ Secondary trading notice
16/04/18		207.33KB	Share
PIQ Conversion of 90% of Proteomics Options raises of $3m
06/04/18	PRICE SENSITIVE	225.84KB	Share
PIQ Change of Director's Interest Notice
06/04/18		234.69KB	Share
PIQ Appendix 3B - Exercise of options
06/04/18		175.61KB	Share
PIQ Secondary trading notice
06/04/18		207.23KB	Share
PIQ Change of Director's Interest Notice
29/03/18		191.24KB	Share
PIQ Appendix 3B - Exercise of options
29/03/18		374.98KB	Share
PIQ Secondary Trading Notice
29/03/18		153.96KB	Share
PIQ Directors Exercise PIQ Options
23/03/18	PRICE SENSITIVE	224.91KB	Share
PIQ Change of Directors' Interest Notices
23/03/18		860.1KB	Share
PIQ Appendix 3B - Exercise of options
23/03/18		374.82KB	Share
PIQ Secondary Trading Notice
23/03/18		166.47KB	Share
PIQ Appendix 3B - Expiry of Options
15/03/18		491.59KB	Share
PIQ Proteomics secures underwriting - PIQ Options to raise $3.4m
14/03/18	PRICE SENSITIVE	224.38KB	Share
PIQ Secondary trading notice
08/03/18		207.24KB	Share
PIQ Appendix 3B
08/03/18		380.01KB	Share
PIQ Proteomics launches PromarkerD
07/03/18	PRICE SENSITIVE	230.91KB	Share
PIQ Proteomics completes investment in CPR Pharma Services
05/03/18		214.91KB	Share
PIQ Appendix 3B
05/03/18		177.62KB	Share
PIQ Secondary trading notice
05/03/18		161.47KB	Share
PIQ Expiry of Options - Letter to Option Holders
19/02/18		1.15MB	Share
PIQ Appendix 4D and Interim Financial Report
16/02/18	PRICE SENSITIVE	1.22MB	Share
PIQ Appendix 3B
15/02/18		388.02KB	Share
PIQ Proteomics International Investor Presentation
07/02/18		3.75MB	Share
PIQ Proteomics International Investor conference call
06/02/18		205.75KB	Share
PIQ Proteomics International Options PIQO Exercised
05/02/18		209.46KB	Share
PIQ Appendix 3B
05/02/18		171.02KB	Share
PIQ Strategic alliance and investment in CPR Pharma Services
02/02/18	PRICE SENSITIVE	229.41KB	Share
PIQ PromarkerD diabetic kidney disease patent granted in Japan
29/01/18	PRICE SENSITIVE	239.31KB	Share
PIQ Appendix 4C - December 2017 Quarterly Report
25/01/18	PRICE SENSITIVE	336.46KB	Share
PIQ Proteomics partners diagnostic test with Dimerix kidney drug
14/12/17		233.2KB	Share
PIQ DXB: Proteomics partnership to improve treatment of CKD
14/12/17	PRICE SENSITIVE	134.42KB	Share
PIQ Proteomics joins major health study to target lung disease
04/12/17	PRICE SENSITIVE	233.22KB	Share
PIQ Results of Meeting
28/11/17		626.64KB	Share
PIQ Proteomics AGM Presentation
28/11/17		3.19MB	Share
PIQ PromarkerD predictive diagnostic test to launch in Q1 2018
27/11/17	PRICE SENSITIVE	263.58KB	Share
PIQ Initial Director's Interest Notice
23/11/17		316.4KB	Share
PIQ Proteomics strengthens Board and Business Development team
22/11/17		285.98KB	Share
PIQ Appendix 3B - Issue of Employee Options
03/11/17		175.37KB	Share
PIQ Notice of Annual General Meeting/Proxy Form
27/10/17		1.46MB	Share
PIQ Proteomics partnered consortium to receive $2 million
26/10/17	PRICE SENSITIVE	207.04KB	Share
PIQ Appendix 4C - September 2017 Quarterly Report
25/10/17	PRICE SENSITIVE	343.23KB	Share
PIQ Proteomics receives R&D tax incentive
10/10/17	PRICE SENSITIVE	219.89KB	Share
PIQ Change in substantial holding
18/09/17		7.82MB	Share
PIQ Change of Director's Interest Notice
13/09/17		124.95KB	Share
PIQ PromarkerD predictive test results published - Diabetes Care
06/09/17	PRICE SENSITIVE	251.98KB	Share
PIQ Annual Report to shareholders
31/08/17		10.53MB	Share
PIQ Corporate Governance Statement and Appendix 4G
31/08/17		349.5KB	Share
PIQ Preliminary Final Report
31/08/17	PRICE SENSITIVE	693.33KB	Share
PIQ Appendix 3B
17/08/17		757.5KB	Share
PIQ Results of Meeting
17/08/17		548.19KB	Share
PIQ US PromarkerD patent expanded to all kidney disease
16/08/17	PRICE SENSITIVE	230.17KB	Share
PIQ Appendix 4C - corrected
28/07/17	PRICE SENSITIVE	773.3KB	Share
PIQ Appendix 4C - June 2017 Quarterly Report
27/07/17	PRICE SENSITIVE	746.98KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 38.0¢		Change 0.000(0.00%)		Mkt cap ! $62.19M

Open	High	Low	Value	Volume
39.0¢	40.0¢	38.0¢	$58.62K	150.4K

Buyers (Bids)

No.	Vol.	Price($)
2	12180	37.0¢

Sellers (Offers)

Price($)	Vol.	No.
38.5¢	5203	1

View Market Depth

No.	Vol.	Price($)
2	12180	0.370
1	36	0.360
2	31937	0.355
2	6428	0.350
1	2898	0.345

Price($)	Vol.	No.
0.385	5203	1
0.400	26318	4
0.410	100000	1
0.425	2775	1
0.440	1983	1

Last trade - 15.42pm 08/08/2025 (20 minute delay)

PIQ (ASX) Chart

PROTEOMICS INTERNATIONAL LABORATORIES LTD - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available